Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 58.07 USD -0.82% Market Closed
Market Cap: 11.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+15%
Revenue
Forecast
+27%
Operating Income
Forecast
+25%
Net Income
Forecast
+25%

Wall Street
Price Targets

BMRN Price Targets Summary
Biomarin Pharmaceutical Inc

Wall Street analysts forecast BMRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMRN is 97.98 USD with a low forecast of 65.65 USD and a high forecast of 132.3 USD.

BMRN Lowest Forecast
Wall Street Target
65.65 USD
13% Upside
BMRN Average Forecast
Wall Street Target
97.98 USD
69% Upside
BMRN Highest Forecast
Wall Street Target
132.3 USD
128% Upside
Lowest
Price Target
65.65 USD
13% Upside
Average
Price Target
97.98 USD
69% Upside
Highest
Price Target
132.3 USD
128% Upside
Biomarin Pharmaceutical Inc Competitors:
Price Targets
TGTX
TG Therapeutics Inc
23% Upside
S
2696
Shanghai Henlius Biotech Inc
23% Downside
ARGX
argenx SE
38% Upside
A
ALVO
Alvotech SA
60% Upside
TGTX
TG Therapeutics Inc
23% Upside
S
2696
Shanghai Henlius Biotech Inc
23% Downside
ARGX
argenx SE
38% Upside
A
ALVO
Alvotech SA
60% Upside
C
2487
Cutia Therapeutics
14% Upside
B
BAVA
Bavarian Nordic A/S
61% Upside
4597
Solasia Pharma KK
78% Upside
6160
Beigene Ltd
2% Upside

Revenue
Forecast

Revenue Estimate
Biomarin Pharmaceutical Inc

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 12%. The projected CAGR for the next 3 years is 10%.

12%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 3 years is 29%.

N/A
Past Growth
29%
Estimated Growth
Estimates Accuracy
13%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Biomarin Pharmaceutical Inc

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 3 years is 33%.

N/A
Past Growth
33%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

See Also

Summary
BMRN intrinsic value, competitors valuation, and company profile.
DCF Valuation
BMRN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BMRN stock valuation using valuation multiples.
Wall Street Estimates
BMRN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BMRN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BMRN's stock price target?
Price Target
97.98 USD

According to Wall Street analysts, the average 1-year price target for BMRN is 97.98 USD with a low forecast of 65.65 USD and a high forecast of 132.3 USD.

What is Biomarin Pharmaceutical Inc's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Biomarin Pharmaceutical Inc's revenue is 12%. The projected CAGR for the next 3 years is 10%.

What is Biomarin Pharmaceutical Inc's Operating Income forecast?
Projected CAGR
29%

The compound annual growth rate of Biomarin Pharmaceutical Inc's operating income for the next 3 years is 29%.

What is Biomarin Pharmaceutical Inc's Net Income forecast?
Projected CAGR
33%

The compound annual growth rate of Biomarin Pharmaceutical Inc's net income for the next 3 years is 33%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.